证券代码：600976 证券简称：健民集团 公告编号：2023-034 健民药业集团股份有限公司 关于《2022 年限制性股票激励计划》所涉限制性股票 首次解锁上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 184,800 股。 本次股票上市流通总数为 184,800 股。 本次股票上市流通日期为 2023 年 9 月 21 日。 （一）《2022 年激励计划》主要内容 公司《2022 年激励计划》股份来源为从二级市场回购的公司 A 股普通股股 票，采用限制性股票的激励方式，向何勤董事长等 6 名激励对象授予的限制性股票 数量为 369,600 股，占公司股本总额 153,398,600 股的 0.24%，无预留股份。 《2022 年激励计划》所涉限制性股票的授予价格为 20.58 元/股，授予日为 2022 年 9 月 5 日。《2022 年激励计划》公司层面的业绩考核以 2021 年归属于上市公司 股东的净利润 32,473.6 ...

湖北得伟君尚律师事务所 关于健民药业集团股份有限公司 2022 年限制性股票激励计划 首次解锁期解锁条件成就的 法律意见书 二○二三年九月十五日 湖北得伟君尚律师事务所 地址：武汉市江汉区建设大道 588 号卓尔国际中心 20 楼、21 楼 电话：（86 27 8562 0999） 电子邮箱：dewell@dewellcn.com 邮政编码：430024 湖北得伟君尚律师事务所 关于健民药业集团股份有限公司 2022 年限制性股票激励计划 首次解锁期解锁条件成就的 法律意见书 致：健民药业集团股份有限公司 湖北得伟君尚律师事务所（以下称"本所"）接受健民药业集团 股份有限公司（以下称"健民集团"或"公司"）委托，作为公司《2022 年限制性股票激励计划》（以下简称《激励计划》）的专项法律顾问， 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人 民共和国证券法》（以下简称《证券法》）、《上市公司股权激励管 理办法》（以下简称《管理办法》）等法律、行政法规、部门规章及 规范性文件（以下简称法律法规）和《健民药业集团股份有限公司章 程》（以下简称《公司章程》）的有关规定，就公司本次限制性股票 激励计划首 ...

公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司于 2023 年 9 月 12 日发出召开第十届董事会第十五次 会议的通知，并于 2023 年 9 月 15 日以通讯方式召开本次会议，会议应参与表决的董 事 9 人,实际参与表决的董事 9 人，符合《公司法》和《公司章程》的规定。经到会董 事充分讨论，审议通过如下议案： 1、关于《2022 年限制性股票激励计划》所涉限制性股票首次解锁的议案 同意：7 票 弃权：0 票 反对：0 票 回避：2 票 何勤董事长、汪俊董事为本议案的受益人，回避表决。 公司《2022 年限制性股票激励计划》于 2023 年 9 月 16 日进入解锁期，首个解锁 期解锁条件成就，可解锁股份 184,800 股将于 2023 年 9 月 21 日解锁并上市流通，详 见上海证券交易所网站（http://www.sse.com.cn）及指定媒体公司披露的《健民药业 集团股份有限公司关于<2022 年限制性股票激励计划>所涉限制性股票首次解锁上市的 公告》。 2、关于调整董事会专门委 ...

关于公司《2022 年限制性股票激励计划》首次解锁激励 对象名单的核查意见 （4）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； 健民药业集团股份有限公司监事会 健民药业集团股份有限公司（以下简称"公司"）监事会根据《公司法》、《证 券法》《上市公司股权激励管理办法》（以下简称：管理办法）等有关法律、法规 和规范性文件以及公司《2022 年限制性股票激励计划》（以下简称：激励计划） 和《公司章程》的有关规定，监事会对公司《激励计划》首次解锁激励对象名单 进行审核，发表如下意见： 1、公司《激励计划》首次解锁激励对象不存在《管理办法》规定的不得成 为激励对象下列情形： （1）最近 12 个月内被证券交易所认定为不适当人选； （2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政处 罚或者采取市场禁入措施； 3、公司不存在法律、法规和规范性文件规定的不得实施股权激励的情形； 公司未发生《激励计划》）中规定的不得解除限售的情形，经董事会确认公司层 面的业绩考核指标已达成。 综上，监事会认为公司《激励计划》首次解锁所涉激励 ...

证券代码：600976 证券简称：健民集团 公告编号：2023-033 健民药业集团股份有限公司 特此公告。 健民药业集团股份有限公司 第十届监事会第七次会议决议公告 监 事 会 二○二三年九月十六日 同意：5 票 弃权：0 票 反对：0 票 监事会对《2022 年限制性股票激励计划》（以下简称《激励计划》）首次解锁所 涉激励对象进行核查，并发表了相关核查意见，监事会认为本次解锁的 6 名激励对 象符合《激励计划》规定的解锁条件，同意解锁相关事宜，详见上海证券交易所网 站(www.sse.com.cn)与本公告一起披露的《健民药业集团股份有限公司监事会关于 〈2022 年限制性股票激励计划〉首次解锁激励对象名单的核查意见》及《健民药业 集团股份有限公司关于<2022 年限制性股票激励计划>所涉限制性股票首次解锁上 市的公告》。 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司于 2023 年 9 月 12 日发出召开第十届监事会第七次 会议的通知，并于 2023 年 9 月 15 日以通讯方式召开本 ...

证券代码：600976 证券简称：健民集团 公告编号：2023-031 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、交易概述 经健民药业集团股份有限公司（以下简称：公司）2021 年第五次临时股东大 会批准，公司作为有限合伙人与关联方杭州华方创量投资管理有限公司（以下简 称：华方创量）、昆药集团股份有限公司等共同参与关联方杭州华方和昂投资管 理合伙企业（有限合伙）（以下简称：华方和昂基金）基金份额的认购，其中公 司以自有资金出资 5,000 万元，占华方和昂基金 49.505%的基金份额，详见公司 于 2021 年 12 月 15 日披露的《关于对外投资暨关联交易的公告》。 二、相关进展 近日，公司收到华方和昂基金管理人相关通知，根据相关法律法规的要求， 合伙企业华方和昂基金已全部完成实缴出资，实际募集资金人民币 1.01 亿元。 各合伙人实缴出资情况如下： | 投资人名称 | 类型 | 出资 | 实缴出资额（万元） | 实缴比例 | | --- | --- | --- | --- | --- | | | | 方 ...

Financial Performance - In the first half of 2023, the company achieved operating revenue of RMB 2.161 billion, a year-on-year increase of 17.67%[20] - The net profit attributable to shareholders of the listed company was RMB 252 million, representing a year-on-year growth of 34.14%[20] - The growth in net profit was primarily driven by increased revenue from key products such as Longmu Bone Strengthening Granules and investment income from joint ventures[20] - The increase in industrial revenue was attributed to enhanced product quality, increased market investment, and expansion efforts, leading to sustained sales growth in both OTC and Rx product lines[20] - The pharmaceutical commercial segment saw revenue growth due to new business development by subsidiary companies[20] - The company achieved a revenue of CNY 216,143.03 million in H1 2023, compared to CNY 183,685.86 million in H1 2022, marking an increase of 17.7%[27] - The pharmaceutical segment contributed CNY 112,466.66 million to the total revenue in H1 2023, up from CNY 90,418.34 million in H1 2022, reflecting a growth of 24.4%[27] - Basic earnings per share for the first half of 2023 were CNY 1.65, an increase of 33.06% compared to CNY 1.24 in the same period last year[38] Market and Industry Trends - The aging population in China has reached 264 million people aged 60 and above, representing 18.7% of the total population, indicating significant growth potential for the pharmaceutical industry[23] - In the first half of 2023, the pharmaceutical manufacturing industry reported a revenue of CNY 212,496 million, a year-on-year decrease of 2.9%, and a total profit of CNY 1,794.5 million, down 17.1% year-on-year[22] - The overall sales scale of traditional Chinese medicine in public hospitals reached 251.2 billion CNY in 2022, with a year-on-year growth of 0.24%[46] - The sales scale of traditional Chinese medicine in urban pharmacies was 129.2 billion CNY in 2022, showing a year-on-year increase of 13.83%[46] Research and Development - The company holds 131 valid patents, including 72 invention patents, and has 71 projects under research, with 27 new drug development projects[26] - The company is actively involved in innovation-driven transformation, with R&D investment expected to grow by over 10% annually according to national policies[23] - R&D expenses increased due to heightened investment in new projects, reflecting the company's commitment to innovation[54] - The company plans to enhance R&D investment to improve overall competitiveness in response to industry policy changes and market conditions[87] Environmental and Sustainability Initiatives - The company has established a comprehensive wastewater treatment station with a daily processing capacity of 800 tons, operating stably 24 hours a day[97] - The company’s wastewater discharge meets the standards after treatment, with COD at 104.4 mg/L against a limit of 500 mg/L, and ammonia nitrogen at 0.82 mg/L against a limit of 45 mg/L[95] - The company has implemented a comprehensive environmental management system, integrating it into management assessments to enhance accountability[102] - The company’s solid waste from production is recycled into organic fertilizers, demonstrating a commitment to sustainability[97] - The company has committed to sustainable development and has been actively involved in clean production and pollution prevention initiatives[157] Financial Position and Investments - The company's cash and cash equivalents at the end of the reporting period amounted to CNY 399,342,069.20, an increase from CNY 219,334,423.78 at the beginning of the period[133] - The company reported a total of CNY 12,002,906.43 in commercial acceptance bills receivable at the end of the period, up from CNY 5,267,070.54 at the beginning[137] - The company has completed a total investment of 50 million yuan in the Hangzhou Huafang and Ang Investment Management Partnership, accounting for 49.505% of the fund's registered capital[60] - The company has also invested 20 million yuan in the Hangzhou Chaosheng Phase II Venture Capital Partnership, representing 9.8% of the fund's registered capital, with 8 million yuan already contributed[60] Corporate Governance and Compliance - The company emphasizes the importance of accurate financial reporting and has management responsible for the integrity of the financial statements[6] - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties during the reporting period[145] - The company has not faced any legal violations or penalties involving its directors, supervisors, senior management, or controlling shareholders during the reporting period[145] - The company has not made any significant changes to its important accounting policies and estimates during the reporting period[154] Community Engagement and Social Responsibility - The company invested a total of 120,000 CNY in poverty alleviation and rural revitalization projects, helping 100 impoverished students in the first half of 2023[159] - The company has engaged in various public welfare activities, including educational support initiatives in collaboration with the Zhejiang Green Shared Education Foundation[159]

证券代码：600976 证券简称：健民集团 公告编号：2023-030 健民药业集团股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 08 月 16 日(星期三)下午 15:00-16:00 会议召开地点：上证路演中心（网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 09 日(星期三)至 08 月 15 日(星期二)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （ir.jmjt@whjm.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间： ...

证券代码：600976 证券简称：健民集团 公告编号：2023-017 健民药业集团股份有限公司 关于参加 2023 年湖北辖区上市公司 投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 5 月 25 日（星期四）14：55-16：30 会议召开地点："全景路演"（http://rs.p5w.net/）网络平台 会议召开方式：网络文字互动 预征集投资者提问的相关安排：投资者可在 2023 年 5 月 24 日（星期三） 17:00 前登录（http://rs.p5w.net/zj/）"问题征集专题"或通过公司邮箱 （ir.jmjt@whjm.com）进行提问，公司将在本次活动上就投资者普遍关注的问题 进行回答。 为进一步加强与广大投资者的互动交流，根据湖北省上市公司协会《关于举 办 2023 年湖北辖区上市公司投资者网上集体接待日活动的通知》，健民药业集 团股份有限公司（以下简称"公司"）将于 2023 年 5 月 25 日下午 14：55-16： ...

Revenue and Profit - Revenue for the first quarter of 2023 reached CNY 1,013,386,110.35, representing a 10.40% increase compared to the same period last year[7] - Net profit attributable to shareholders of the listed company was CNY 99,560,117.11, reflecting a 12.23% increase year-over-year[7] - The basic earnings per share for the first quarter was CNY 0.65, a 12.56% increase year-over-year[7] - Net profit for the first quarter of 2023 reached ¥99,813,628.68, an increase from ¥88,756,974.61 in the same period of 2022, representing a growth of approximately 12.4%[34] - Basic and diluted earnings per share for Q1 2023 were both ¥0.65, up from ¥0.58 in Q1 2022, indicating an increase of 12.1%[34] - The company’s total comprehensive income for Q1 2023 was ¥99,813,628.68, compared to ¥88,756,974.61 in Q1 2022, showing an increase of about 12.4%[34] Cash Flow and Operating Activities - Net cash flow from operating activities decreased to -CNY 66,838,774.27, showing a significant improvement of 44.69% compared to the previous year[7] - In Q1 2023, the company reported cash inflows from operating activities totaling CNY 826,038,702.59, an increase of 14.2% compared to CNY 723,829,244.73 in Q1 2022[21] - The net cash outflow from operating activities was CNY -66,838,774.27, an improvement from CNY -120,835,996.96 in the same period last year[21] - The cash paid for purchasing goods and services was CNY 428,200,019.75, a decrease of 5.8% compared to CNY 454,578,829.20 in Q1 2022[21] - The company reported a net cash inflow from investing activities of ¥158,475,384.12 for Q1 2023, compared to ¥95,307,711.30 in Q1 2022, indicating an increase of approximately 66.2%[42] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,666,150,710.72, an increase of 6.65% from the end of the previous year[9] - Total assets as of March 31, 2023, amounted to ¥3,666,150,710.72, compared to ¥3,437,659,256.29 at the end of 2022, reflecting a growth of about 6.7%[37] - Current assets totaled ¥2,717,074,819.60 as of March 31, 2023, an increase from ¥2,304,736,978.02 at the end of 2022, marking a rise of approximately 17.9%[36] - Total liabilities increased to CNY 1,696,783,275.43 from CNY 1,569,824,934.23, reflecting a growth of 8.1% year-over-year[32] - Total liabilities as of March 31, 2023, were ¥1,655,005,193.83, up from ¥1,533,677,772.65 at the end of 2022, reflecting an increase of about 7.9%[37] - The company’s short-term borrowings rose to ¥78,460,688.42 in Q1 2023, compared to ¥22,515,625.00 in the same period of 2022, indicating a significant increase of approximately 248.5%[37] Shareholder Information - Shareholders' equity attributable to the listed company was CNY 1,964,141,209.15, up 5.44% from the previous year[9] - The total equity attributable to shareholders rose to CNY 1,964,141,209.15, up from CNY 1,862,861,607.49, indicating a year-over-year increase of 5.4%[32] - The company reported a total of 10,407 shareholders as of the end of the reporting period[27] - The top ten shareholders held a combined total of 56,000,000 shares, representing approximately 36.5% of the total shares outstanding[27] Investment and Income - Investment income for the period was CNY 44,001,851.68, compared to CNY 40,608,498.78 in the previous year[19] - The company received investment income of CNY 96,327,867.94, an increase from CNY 82,013,315.69 in the previous year[21] - The company received government subsidies amounting to CNY 3,340,449.77, which are closely related to its normal business operations[3] Accounting and Reporting - The company has implemented new accounting standards starting from 2023, which may affect the financial statements[45] - The first quarter report for 2023 has been released, detailing the company's financial performance[46] - The board of directors and management have confirmed the accuracy and completeness of the quarterly report, ensuring no misleading statements or omissions[48] - The financial statements for the first quarter have not been audited, indicating preliminary figures[49]